CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: July 28, 2020
Result type: Reports
Project Number: SR0641-000
Product Line: Common Drug Review

Generic Name: fremanezumab

Brand Name: Ajovy

Manufacturer: Teva Canada Innovation

Indications: migraine

Manufacturer Requested Reimbursement Criteria1: To be confirmed later in the submission.

Submission Type: New

Project Status: Received

Companion Diagnostics: No

Fee Schedule: Pending

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient input openMarch 30, 2020
Call for patient input closedMay 20, 2020

- Patient input submission received from Migraine Canada and Migraine Quebec

Submission receivedJune 03, 2020
Submission accepted-

- Submission was not accepted for review on 17 June 2020